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PERSPECTIVES IN CLINICAL NEPHROLOGY
Chronic cyclosporine nephropathy: The Achilles' heel of
immunosuppressive therapy
In the past 15 years, short-term success rates for allografts of
kidney, heart, liver, and kidney/pancreas have reached unprece-
dented levels largely due to cyclosporine-based immunosuppres-
sive regimens. Most transplant centers around the world achieve
85 to 90% one-year graft survival for kidney transplants and very
few patients suffer loss of life because of modern medical man-
agement [1, 2]. These impressive results with cyclosporine have
extended the indications for cyclosporine usage from organ
transplantation to the treatment of autoimmune and primary
renal diseases. However, nephrotoxicity due to cyclosporine con-
tinues to be a major problem [3]. In spite of improved one- and
two-year renal allograft graft survival rates, the average half-life of
eight years for a cadaver kidney transplant that is functioning at
one year has changed little with the addition of cyclosporine-
based immunosuppression [4, 1. Conventional wisdom suggests
that chronic allograft failure in kidney transplants is largely due to
chronic rejection [6]. However, the adverse effects of cyclosporine
on long-term kidney structure and function have not been ex-
cluded as an important part of the chronic allograft failure
syndrome. An important role for cyclosporine on chronic progres-
sive renal dysfunction when used outside the renal transplant
situation is well accepted. This communication will review the
entity of chronic cyclosporine nephropathy. The current literature
about this subject will be analyzed and its presumed pathogenesis
will be reviewed with an emphasis on recent studies indicating that
cyclosporine-induced renal fibrosis may be an inevitable conse-
quence of effective immunosuppressive therapy.
Renal effects of cyclosporine
It is well-known that cyclosporine causes a dose-related de-
crease in renal function in experimental animals and humans. This
is largely thought to be due to the drug's hemodynamic effects to
produce afferent arteriolar vasoconstriction and in the extreme,
decreased glomerular filtration rate (GFR), manifested clinically
by rises in serum creatinine [7, 8]. While there are many candidate
mediators for cyclosporine-induced vasoconstriction such as en-
dothelin, thromboxane A2, nitric oxide synthase inhibition and
activation of the sympathetic nervous system, these effects are
reversible with dose reduction or appropriate pharmacologic
maneuvers [9—14]. The studies of Curtis et al [151 have shown that
even in renal transplant patients who are perceived to be doing
well under cyclosporine immunosuppression, drug withdrawal
leads to rapid improvement in renal hemodynamics. While some
have argued that these cyclosporine-induced renal effects can be
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successfully managed with precise pharmacologic monitoring and
improved dosing, these presumptions depend on the assumption
that cyclosporine-induced nephropathy is functional, dose-re-
lated, and reversible. These acute hemodynamic effects may not
be the only consequences of cyclosporine on the kidney. It is clear
that the morphologic lesion produced by cyclosporine therapy in
patients with autoimmune diseases, extrarenal organ transplant
recipients, renal allograft recipients, and experimental animals,
consists of areas of striped tubulointerstitial fibrosis, tubular
atrophy and afferent arteriolopathy [16, 17]. The process begins in
the outer medulla with extension to the medullary rays and thus is
often difficult to diagnose on a core renal biopsy. The hallmark of
cyclosporine nephropathy rests on the demonstration of appro-
priate vascular lesions in the afferent arteriole (cyclosporine-
associated arteriolopathy) [161. These vascular lesions of chronic
cyclosporine nephropathy are not necessarily dose-related and in
some patients can be observed with doses of cyclosporine as low
as 2 to 4 mg/kg.
Many of the retrospective clinical reports concerning the pres-
ence or absence of chronic cyclosporine nephropathy in renal
transplantation are based on renal function alone [181. There are
few pathologic data available to separate chronic allograft rejec-
tion from chronic cyclosporine nephropathy. This distinction is
based on the demonstration of arteriolar vessel changes as
opposed to the arterial lesions of chronic rejection [16]. In
addition, there is also no a priori reason that both processes
cannot exist together. Thus, for the most part, renal function as
estimated by serum creatinine or even by more precise GFR
measurements has been used as a surrogate marker for the
presence or absence of chronic cyclosporine nephropathy. Clearly,
adaptive mechanisms within the kidney can keep the GFR
relatively stable for long periods in the face of progressive and
important tubulointerstitial disease as exemplified by diabetic
nephropathy, autosomal dominant polycystic kidney disease, and
non-cyclosporine-treated renal transplants [19].
Chronic cyclosporine nephropathy
Chronic cyclosporine nephropathy is defined as a clinicopath-
ologic entity produced by exposure of the patient to cyclosporirie.
characterized by tubulointerstitial fibrosis in a striped pattern,
beginning in the medulla and progressing to the medullary rays of
the cortex. It is associated with degenerative hyaline changes in
the walls of afferent arteriolar-sized blood vessels extending from
the pre-glomerular area proximally up the afferent arteriole [161.
Usually, but not inevitably, this pathologic finding is associated
with some degree of renal dysfunction. It is clear that this
clinicopathologic entity does not preclude the coexistence of other
processes such as renal allograft rejection. Dc novo or recurrent
hemolytic uremic syndrome may be associated with cyclosporine
[20, 211. There is glomerular fibrin deposition with fibrin thrombi.
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This unusual type of cyclosporine-associated renal dysfunction
will not be discussed further.
Chronic cyclosporine nephropathy in heart transplantation
The pivotal studies of Myers et al [22] described the renal,
structural, and functional changes in the native kidneys of heart
transplant recipients. Careful documentation of renal function
revealed a progressive decrease in GFR with a concomitant drop
in renal plasma flow and increase in renal vascular resistance. This
was associated with hypertension. Biopsies in a subset of these
patients showed glomeruloscierosis, striped interstitial fibrosis,
and afferent arteriolopathy. The original study was criticized
because of the high doses of cyclosporine that were used for
induction and subsequently for maintenance therapy. The starting
dose of 17 mg/kg/day with adjustment downward, was higher than
that used in modern cardiac transplantation [23]. Nonetheless,
when patients who subsequently underwent heart transplantation
at Stanford with cyclosporine doses of 10 mg/kg or less were
compared with the high dose patients, both groups had hyperten-
sion and decreased GFR. The decrease in GFR was approxi-
mately 45% from baseline, even in the low dose cyclosporine
group, when compared to a historical control group which used
azathioprine and prednisone without cyclosporine. Renal biopsy
samples from patients treated with lower dose cyclosporine had
the same pathologic changes as those seen with higher doses and
no difference in the degree of involvement could be shown [241.
When high dose and low dose groups were compared two years
after transplantation, the mean serum creatinine was 2.1 mg/dl in
the high dose group, 1.6 mg/dl in the low dose group, and 1.2
mg/dl in the no cyclosporine group [25]. It was further demon-
strated that sequential native kidney biopsies in both cyclosporine
groups showed progressive histopathologic changes. There was a
cumulative incidence of end-stage renal disease of approximately
10% from the decade of 1980—1990 [25]. There were no differ-
ences in cardiac function among the groups to explain the renal
dysfunction. Furthermore, the authors established that cyclospor-
me-induced chronic nephropathy can progress despite drug with-
drawal.
Other studies have looked at renal function without concomi-
tant renal pathologic studies in heart transplant recipients. Zietse
et al [26] in 1994 followed 187 patients treated with initial doses of
cyclosporine of 8 mg/kg/day. At two years post-transplant, serum
creatinine was >2 mg/dl in 52% of the patients. At four years,
serum creatinine was >3.5 mg/dl in 13% of the patients. There
was no relationship of renal dysfunction to CSA blood level, the
use of calcium antagonists, blood pressure, or the pre-transplant
serum creatinine. In two publications by Greenburg et al [27, 28],
heart transplant patients were frequently shown to have azotemia
and acute renal failure at one week post transplant. No CsA-
treated patients in this series who had 36 months of follow-up
showed normal renal function. One patient had progressed to
end-stage renal disease. Renal function was improved in five
patients in whom dose reduction was attempted, although patho-
logic documentation of histologic improvement is not available.
These 43 cyclosporine-treated cardiac transplant recipients had a
58% incidence of azotemia compared to 34% of 41 non-cyclos-
porine-treated patients and 4% of 25 patients undergoing cardio-
pulmonary bypass without immunosuppression.
In a later study of 228 adults who survived more than one year
after cardiac transplantation and who had normal renal function
before transplantation, the serum creatinine at hospital discharge
rose from 1.2 mg/dl to 3.3 mg/dl at seven years, and 1.6% of
patients had developed end-stage renal disease by 18 months with
an additional patient developing end-stage renal disease after five
years. No pathologic material was available, but the doses of
cyclosporine used in the study were similar to current clinical
doses of 10 mg/kg/day for induction and then 5 to 10 mg/kg/day
dependent on blood levels.
An autopsy study of 15 patients established that interstitial
fibrosis can be present in terminal heart failure patients before
heart transplantation and it does not inevitably progress [29].
There was no relationship between renal histology and cyclospor-
me-treated heart transplant recipients' blood pressures and serum
creatinine levels. In this study, it was confirmed that cyclosporine
can cause progressive arteriolar hyalinization and glomeruloscle-
rosis.
The remainder of studies in heart transplant recipients involve
renal function only. Studies of 203 recipients by Lewis et al [30],
Gonwa et al [31], showed initial decreases in GFR of approxi-
mately 30% with stabilization of GFR measured directly or
estimated by the reciprocal of serum creatinine. Doses again were
contemporary, and no histopathology was available. Gonwa et a!
[31] cited a 1 to 2% incidence of end-stage renal disease at four
centers with > 1000 patients, although the duration of follow-up
and the current renal function of these patients is unknown.
A particularly important study was performed by Bertani et al
[32]. Renal biopsies were obtained at the same time that renal
functional studies were performed in 10 cyclosporine-treated
heart transplant recipients who had been on the drug for two
years. GFR and effective renal plasma flow were below normal
values in transplant recipients, and the averages were 35 mI/min/
1.73 m2 and 325 ml/min/1.73 m2, respectively. Light microscopy of
autopsy specimens from patients with no history of renal disease
and from patients who had died from dilated cardiomyopathy
without heart transplantation revealed no structural renal abnor-
malities. However, in cyclosporine-treated patients, arteriolopa-
thy and glomerulosclerosis were seen. Thus, cyclosporine given
for more than two years induced in all patients moderate renal
failure associated with obliterative arteriolopathy and glomerular
ischemia. As cyclosporine nephropathy developed, subpopula-
tions of glomeruli of different sizes emerged. Some glomeruli
were small and had segmental or global sclerosis, and other
glomeruli were large. Follow-up of these same patients by Rug-
genenti et al [331 showed stabilization of GFR and renal plasma
flow over a two-year follow-up period. No histopathology was
recorded in the follow-up study.
Nephrotoxicity is frequent and a major cause of progressive
renal injury in lung transplantation. In 30 recipients followed for
at least six months, 50% developed hypertension, 9 patients had
creatinines > 3 mg/dl, and 2 had developed end-stage renal
disease [34]. Likewise, of 67 heart-lung transplant patients surviv-
ing at least six months, 3 developed end-stage renal failure, while
the mean serum creatinine rose from baseline 0.96 to 1.88 at
four-year follow-up [35].
Chronic cyclosporine nephropathy in renal transplantation
The effect of cyclosporine on renal structure and function in
renal allografts is often difficult to discern. Much of the problem
involves the complicated differential diagnosis of renal dysfunc-
tion in this setting [16]. Chronic rejection, recurrent renal disease,
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and nonspecific factors such as hypertension, hyperlipidemia and
age can lead to progressive renal structural and functional dete-
rioration. Discerning the role, if any, of cyclosporine in isolation is
difficult. Based largely on retrospective data showing stability of
serum creatinine over time, it has been stated that the renal
transplant is relatively spared from the ravages of chronic cyclo-
sporine treatment [18]. Many of these studies are methodologi-
cally flawed because both structure and function were not mea-
sured, some studies used structure alone, and some studies used
functional parameters alone. Jacobsen et a! [36] studied 19 renal
transplant patients who received cyclosporine for two years. The
daily dose of cyclosporine was 15 mg/kg to start, dropping to 6
mg/kg at two years. GFR was 42 mI/mm compared to 106 ml/min
in 13 healthy two kidney gender- and age-matched control pa-
tients. Eighteen of the 19 patients had increased tubulointerstitial
fibrosis by morphometric determination when compared to nor-
mal kidneys. All of the recipients were non-diabetic, and there was
no correlation between the degree of renal dysfunction and the
extent of tubulointerstitial fibrosis. Ruiz et al [37] studied 59
cyclosporine-treated kidney transplant patients at 15 weeks post-
transplant and compared them with 46 recipients who did not
receive cyclosporine and with 15 pre-transplant donor kidney
biopsies. The daily dose of cyclosporine at the time of biopsy was
12 mg/kg. Both transplant groups had increased tubulointerstitial
fibrosis when compared to control kidneys. The interstitial fibrosis
was more extensive and the serum creatinine level higher in the
cyclosporine group after six months. Klintmalm et al [38] studied
38 biopsies in 24 cyclosporine-treated renal transplant patients
and compared them to 43 biopsies from 43 patients treated with
azathioprine and steroids over a one to four year observation
period. Doses of cyclosporine, again, were high initially and
tapered to 10 mg/kg/day at four months. Serum creatinine aver-
aged 2.1 mg/dl in the cyclosporine-treated patients and 1.5 mg/dl
in the azathioprine-treated group. Blind analysis of the renal
biopsies showed severe interstitial fibrosis and tubular atrophy in
the cyclosporine patients when compared with biopsies from the
azathioprine patients, although the same number of rejection
crises occurred in each patient group. The renal histologic findings
correlated with high trough cyclosporine levels and cumulative
cyclosporine dose in the first six months.
Other groups in the early 1980s reported that renal biopsies
showed progressive changes of chronic cyclosporine nephropathy.
Sommer et al [39] reported that cyclosporine arteriolopathy
caused graft loss in 7.5% of 200 recipients. This represented 40%
of all allografts that failed. Graft losses not attributable to chronic
rejection also demonstrated interstitial fibrosis.
Perhaps the most cited study is the retrospective analysis of
1415 kidney transplant recipients by Burke et al [40]. This study
followed serum creatinine levels, up to four years after transplan-
tation. Values were elevated but unchanged during the period of
study. Only 25% were followed for more than four years and the
average follow-up was three years. The main drawback of this
study was the absence of renal histopathology. The diagnosis of
"chronic rejection" in this study was based simply on progressive
renal dysfunction in the absence of improvement following cyclo-
sporine dose reduction. Furthermore, the four centers which
contributed to this report, all had different immunosuppressive
regimens. Long-term increases in serum creatinine in cyclospor-
inc-treated HL-A identical renal transplants compared to azathio-
prine-treated patients is of concern [41]. Experimental data from
denervated renal isografts which progressively fail over 12 months
from cyclosporine-induced renal failure do not support a sparing
of renal transplants from CSA toxicity [7]. Other studies without
histopathology or controls, such as those of Lewis et al [42],
Slomovitz et al [43] and Lewis et al [30], showed elevated serum
creatinine levels and decreased GFRs for a solitary kidney that
were abnormal but stable. Since histopathology was not per-
formed, cyclosporine-associated tubulointerstitial disease with
arteriolopathy cannot be excluded. Thus, chronic rejection de-
fined on clinical grounds alone, that is, renal dysfunction, mini-
mizes any role for cyclosporine.
It is possible that cyclosporine-induced injury may play a role in
chronic allograft failure that is caused predominantly by chronic
rejection. Mihatsch et al studied 90 patients and compared renal
pathology in a group who had serum creatinine levels less than 2
mg/dl, with a group who had biopsy-proven rejection with serum
creatinine levels greater than 2 mg/dl, and with a pathologically
defined cyclosporine-nephrotoxicity group with serum creatiriine
levels greater than 2 mg/dI [17]. Of the variables examined, factors
that lead to acute cyclosporine nephrotoxicity such as high trough
blood levels, had predictive value for chronic cyclosporine
changes even in patients whose biopsies showed histologic evi-
dence of acute rejection. Table 1 summarizes the available studies
concerning the long-term effects of cyclosporine on renal struc-
ture and/or function.
While it has been thought that arteriolopathy and tubulointer-
stitial fibrosis are irreversible changes, some recent studies have
questioned this assumption. A preliminary study of 21 patients
with biopsy-proven cyclosporine nephrotoxicity showed that with
50 percent dose reductions in 12 patients and complete cyclospo-
rifle withdrawal in 9 patients, GFR improved from a mean of 42
to 67 mI/mm. In 5 patients who had repeat biopsies, arteriolar
lesions disappeared and "onion skin" vascular changes decreased.
There was only one acute rejection episode noted with these
dosage adjustments [4I.
Morozumi et al [45] in 1992 showed that in 9 of 20 patients
transplanted 10 years earlier, there was no difference in mean
cyclosporine whole blood levels and duration of treatment be-
tween those who had demonstrable arteriolopathy and those who
did not. However, vascular lesions were reversible in patients in
whom the drug was discontinued and renal function became
normal.
Thus, despite 15 years of cyclosporinc-based immunosuppres-
sion in renal transplant recipients, there are no prospective
studies available that document the long-term renal safety of this
compound or the effect of cyclosporine-induced renal structural
and functional changes on the longevity of renal transplants. The
difficulty in implicating cyclosporinc in chronic allograft failure
has arisen because of the complexity of its role in an allograft
under immunologic attack.
yclosporine-induced renal sympathetic nerve stimulation has
been implicated in the development of hypertension in recipients
of non-renal organ transplants [46, 47]. It has been suggested that
renal denervation protects the transplanted kidney versus extra-
renal situations in which cyclosporine is prescribed. Recent ex-
perimental studies, however, have shown that renal denervation
does not protect against chronic cyclosporinc nephropathy [7, 481.
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Table 1. Summary of published articles on long term effects of cyclosporine on renal structure and/or function
Chronic cyclosporine nephropathy in autoimmune disease
Because of the success of cyclosporine in solid organ transplan-
tation, it was logical to extend this potent immunosuppressive
drug to other refractory conditions thought to be of immunologic
origin. In these patients, most clinical trials only enrolled people
with normal renal function because of worries about nephrotox-
icity. Since rejection is not an issue in autoimmune disease, the
pathologic and functional changes produced by cyclosporine are
instructive. One of the first uses of cyclosporine was in patients
with refractory autoimmune uveitis. The NIH group 1491 reported
17 patients who received cyclosporine in initial daily doses of 10
N Renal function Renal pathology CsA dose mg/kg
Length of
follow-up Remarks
Bantle et al 11501 11 Mean GFR None 3—5 mg/kg 23 mo
reduced by 27%
from baseline:
but stable over
study period
Burke et al [1511 1415 Mean scrum
ereatinine 1.9
mg/dl: stable
over study
period
None Regimens varied
among 4 centers
Mean follow-up 3
yrs
Retrospective clinical
definition of
chronic rejection,
CsA nephrotoxicity
Klintmalm [38] 24 pts with CsA
43 pts with
azathioprine
(AZA)
Mean serum
creatinine 2.1
mg/dl with CsA,
1.5 mg/dl with
AZA
Masked pathology;
more fibrosis
and tubular
atrophy in CsA
pts
17.5 mg/kg initial 10
mg/kg at 4 mo
1—4 yrs Rejections equal.
Fibrosis correlated
with high
cumulative CsA
and trough levels in
first 6 mos
Jacobson Ct al [36] 19 GFR 42 mI/mm; P
< 0.001 vs.
healthy controls
18 pts had
increased fibrosis
compared to
controls
12—15 mg/kg initial
4-6 mg/kg at 2
mo
2 yrs
Lewis et xi [30] 119 Mean serum
creatinine
2.1 mg/dl
None 10—14 mg/kg
adjusted to
trough levels
7 mg/kg at 6 mo
4.3 mg/kg at 4 yr
Up to 4 yr Reciprocal creatinine
stable; 32 pts
withdrew because
of nephrotoxicity
Lewis et al [421 44 GFR stable over 1
year period
None Mean dose
4.8 mg/kg
Studied 2 mo to 9
yr post-
transplant
Mourad et al [44J 21 pts with
biopsy-proven
CsA
nephrotoxicity
GFR improved
from 42 to 67
mI/mm when
CsA decreased
In 5 pts, arteriolar
lesions
disappeared
Dose reduced in 50
percent; CsA
discontinued 9
pts
Ruiz et al [37] 59 CsA
46 AZA
or stopped
Creatinine
increased in CsA
Both groups had
increased fibrosis
11.8 mg/kg at time
of biopsy
15 weeks of CSA
group
(P < 0.01)
compared to
pre-transplant
donor controls
Slomowitz [43] 29 Initial GRF 29 ml/
mm in Pt who
lost grafts vs. 46
mI/mm in those
with stable
function
5 graft losses, 3
rejection plus
CsA toxicity, 2
CsA toxicity
alone
Tailored to trough
level 150—250
ng/ml; dose 3.5—
4.9 mg/kg
32 mos
Snider et al [152]
Summer et al [39]
145 with CsA
194 with AZA
200 consecutive
cadaver
transplants
Mean serum
creatinine did
not differ
between groups
None given
None reported
16 serial biopsies
showed
progressive CsA
nephrotoxieity
S mg/kg/day initial
tapered to blood
level target
10 mg/kg/day in
double or triple
therapy regimens
Up to 6 yrs
1 year Cyclosporine toxicity
cause of graft loss
in 15 pts
Sumrani et al [41] HI-A identical
72 with AZA
34 with CsA
Creatinine 2.4 at 5
yrs in CsA pts
with progressive
rise vs stable
ereatinine 1.4, in
azathioprine pts
None 10—15 mg/kg
initially; 4 mg/kg
at 1 yr
Up to 5 yrs Pt and graft survival
better with CsA
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mg/kg. The dose was titrated to keep the serum creatinine level
less than 2 mg/kg or less than 50% above the baseline value.
Duration of therapy was from two to four years. All patients had
arteriotar changes on renal biopsies performed after 18 to 24
months of therapy. In 6 patients, further follow-up biopsies were
available. Three of these showed progressive tubulointerstitial and
arteriolar changes in the presence of stable inulin clearances.
Despite the fact that all patients had normal creatinine clearance
before initiation of cyclosporine therapy, 14 of 17 patients had
markedly reduced renal function, and in 2 of the 17 these renal
function deteriorations were progressive. Two of 17 improved
when the drug was stopped, and 12 of 17 remained stable after
dose reduction. There was little relationship between the patho-
logic changes, the dose, and the whole blood trough blood levels
[49, 50]. Sixteen other patients were treated with cyclosporine
initially, 6 mg/kg/day tapered to 2 mg/kg/day, and followed for five
years. The GFR was reduced from 119 mI/mm to 98 mI/mm
without a return to the pre-treatment level when the drug was
stopped. No pathologic studies were performed in this series [51].
In 1991, Anderson et al [52] reported on 10 patients who initially
received 10 mg/kg/day of CsA that was reduced to 5 mg/kg/day for
three years. Eight of the 10 patients had lymphocytic infiltrates
with arteriolar hyalinosis on renal biopsy. Creatinine clearances
were slightly reduced from baseline values.
Another major use of cyclosporine has been at the onset of
insulin-dependent diabetes mellitus. There are a variety of proto-
cots that have been used, including doses from 7.5 to 10 mg/kg/day
[53]. In a study reported by Assan et a! [54] in 1994, a mean of 13
months of therapy with cyclosporine was evaluated. There were
typical histopathological abnormalities in 40% of patients which
were not progressive when doses were low and adjusted for serum
creatinine levels. The morphologic changes correlated with age,
dose and the trough blood level. Functional abnormalities were
reversible when doses were reduced. Mihatsch et al [55] in 1991
studied 40 type 1 diabetic patients treated with cyclosporine 7 to
9 mg/kg/day for at least one year. Twenty-five percent of the
patients had vascular and interstitial pathologic changes of
chronic cyclosporine nephropathy. Renal function, as measured
by serum creatinine level, was decreased by 43% at the time of
biopsy when compared to baseline values. The patients of Mi-
hatsch were different than the patients of Assari et at whose
patients were biopsied when in remission from type I diabetes
[54]. There was a weak positive correlation of high trough
cyclosporine levels with chronic cyclosporine nephropathy.
Feutren and Mihatsch reported an extensive series of autoim-
mune patients with pathologically defined chronic cyclosporine
nephropathy [56]. Initial cyclosporinc dose, male gender and
cpisodes of acute nephrotoxicity correlated with the presence of
chronic changes. It is noteworthy that patients in this series were
young and without previous renal dysfunction or atherosclerosis.
In diabetic subjects who achieved five years of normoglycemia by
pancreas alone transplants, serious tubulointerstitial and gb-
merulosclerotic lesions developed in native kidneys. This con-
trasted with a lack of renal abnormalities in control diabetics with
similar baseline renal function followed for the five year period
[57].
Series of psoriasis patients who received low doses of cyclospo-
rifle, initially 5 mg/kg/day, tapered to 1 to 2 mg/kg/day, have shown
moderate arteriolopathy and scarring [6, 58—61]. In the studies
that have reported renal pathology, arteriolopathy and tuhuloin-
terstitial fibrosis have been seen associated with decreased GFR
[62]. Serial biopsies one year apart have shown increases in renal
fibrous tissue inversely correlated with creatinine clearance [63,
64]. In psoriatic patients, there were correlations between acute
episodes of nephrotoxicity and chronic changes, but no relation-
ship to dose, duration of therapy or blood levels. An excellent
prospective study by Young et al with serial biopsies and GFR
measurements showed a decline of 3.1 ml/min/i.73 m2/year along
with progressive structural changes [65]. Angiotensin II elevations
were noted in patients with cyclosporine A (CsA)-associated
hemodynamic abnormalities [66]. Similar findings to the psoriasis
series were noted in atopic dermatitis treated with cyclosporine
[67].
In a two-year placebo controlled study in multiple sclerosis
patients, serum creatinine rose from baseline normal values to
greater than ito 5 times baseline or greater than 2 mg/dl in 21%
of 273 patients randomized to CsA with blood pressure elevations
in 50%. No biopsies were done [68]. Low dose cyclosporine
produced chronic cyclosporine nephropathy in serial biopsies
from rheumatoid arthritis patients with no previous renal disease,
as well as in increases in serum creatinine [69—75]. A 24-month
serial biopsy in 11 patients were compared to 22 matched autopsy
controls who had received gold and/or penicillamine [76]. Al-
though creatinine clearance decreased from lii mi/mm to 82
mi/mm, structural nephropathy was minimal. Mild tubular atro-
phy was common but arteriolopathy was only found in 3 biopsies
[76]. Structural nephropathy of a similar degree was seen in
controls. Similar data exist for patients with myasthenia gravis and
other autoimmune diseases in blinded clinical trials [77—82].
Chronic cyclosporine nephropathy in liver transplantation
Several series have been reported in which renal function has
been followed in liver transplant patients [83—86]. While GFR
decreases soon after liver transplantation, renal dysfunction is
seldom progressive, at least up to three or four years of follow-up.
However, renal histopathobogic changes have not been extensively
studied.
In one recent study where autopsy pathology in 7 liver trans-
plant patients was compared to that of gender and age matched
controls, cyclosporine caused progressive fibrosis and arteriolopa-
thy independent of serum creatinine levels and blood pressure
[87].
In a large series of liver transplant patients [88], the greatest
decline in creatinine clearance occurred at 18 months. However,
at three years post-transplant, serum creatinine was less than 1.7
mg/dl in only 23% of patients. There was no relationship between
kidney dysfunction and the daily dose of cyclosporine or the
measured whole blood trough blood levels. Thus, in liver trans-
plantation, as in other solid organ transplantation, cyclosporine
induces important structural and functional lesions.
Bone marrow transplantation
In bone marrow transplantation, where cyclosporine is used as
prophylaxis against graft versus host disease, Dieterle et a! [89]
reported renal pathology in autopsied or biopsied bone marrow
transplant recipients. Striped interstitial fibrosis was present in 25
patients, and arteriolopathy was present in 36 patients of the 51
patients studied. Serum creatinine levels increased 40 to 80% by
three months post-transplant and stabilized. The renal pathology
seemed to be worse when total body radiation was used to
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condition the bone marrow transplant recipient even when the
kidneys are shielded. Bone marrow recipients tended to be
younger and without pre-existing atherosclerotic disease when
compared to recipients of other organs. This demonstrated that
chronic cyclosporine nephropathy may occur without those risk
factors. An autopsy study of 112 bone marrow transplant recipi-
ents showed that 54% has vascular and interstitial toxic lesions
with severe thrombotic microangiopathy in 25% [901.
Primary renal disease and cyclosporine
When cyclosporine is used to treat nephrotic syndrome or
glomerular diseases, any renal function deterioration is not easily
distinguished from progression of the primary diseases process.
Delaney, Dukes and Edmunds [91] reported 10 adult patients with
nephrotic syndrome of various causes treated with cyclosporine 5
mg/kg for up to five years. Three patients had mild elevations of
serum creatinine while in one patient abnormal renal function
improved. No follow-up biopsies were done. In children, GFR
falls within the first three months by 21% but remains stable
thereafter up to two years [92]. In 42 nephrotic children with pre-
and post-treatment renal biopsies, Habib and Niaudet were able
to demonstrate progressive tubulointerstitial changes and arteriol-
opathy in the absence of progressive focal glomerulosclerosis
lesions suggesting cyclosporine nephrotoxicity in 9 patients [93,
94]. Interestingly, there was normal renal function and no corre-
lation between the pathologic lesions and the treatment dose,
duration, or trough blood levels. Meyrier et al found that minimal
change nephrotic syndrome patients tolerated cyclosporine up to
5.5 mg/kg well without histologic evidence of nephrotoxicity,
whereas patients with focal and segmental glomerulosclerosis
particularly with pre-existing renal insufficiency were at risk of
cyclosporine nephrotoxicity [5I.
This subject has recently been debated [96, 97]. A randomized
controlled trial of cyclosporine in membranous nephropathy has
showed slowing of progressive renal dysfunction and decreased
proteinuria in patients with refractory nephrotic syndrome. No
follow-up renal histology was available [98]. Biopsies of patients
with lupus nephritis 18 to 24 months after steroids and 5 mg/kg/
day cyclosporine revealed no evidence of chronic cyclosporine
nephropathy [99]. Thus, cyclosporine can produce chronic ne-
phropathy when the drug is used to treat renal diseases although
the risk to long-term renal reserve is unclear.
Pathophysiology of chronic cyclosporine nephropathy
Cyclosporine is known to produce decreases in renal blood flow
due to constriction of the afferent arteriole proximal to the
glomerulus [8]. Although most of these studies have been per-
formed in experimental animals, similar phenomena occur in
humans. The profound impairment of renal hemodynamics from
even a single dose of cyclosporine in chronically treated renal
transplant patients has been documented by Perico et al [10]. In
stable patients who have cyclosporine discontinued, renal blood
flow improves by 30% and renovascular resistance and blood
pressure reciprocally drop [151. Thus, some degree of renal
vasoconstriction probably occurs in all patients who receive
effective immunosuppressive therapy with eyclosporine. When
this hemodynamically-mediated phenomenon causes a rise in
serum creatinine, which is reversible with dosage adjustment, the
clinical diagnosis of acute cyclosporine ncphrotoxicity is made.
Animal models of chronic cyclosporine nephrotoxicity have
been difficult to develop. Even in animals treated with cyclospo-
rifle for long periods of time, or with extremely high doses, the
adverse renal hemodynamic effects are not associated with major
structural abnormalities in the kidney [100]. Tubular function, in
response to the vasoconstriction, is well preserved, at least as
measured by the fractional excretion of sodium and lithium [8].
There is little evidence for acute tubular necrosis produced by
cyclosporine. While prolonged vasoconstriction could contribute
to chronic cyclosporine nephropathy by producing chronic isch-
emia, this relationship has been difficult to demonstrate in exper-
imental studies. Thus, most studies in salt replete animals even
with extremely high blood levels for periods as long as 12 months
have failed to reproduce the clinicopathologic findings of chronic
cyclosporine nephropathy observed in humans [100].
There are many suggested mediators for cyclosporine-induced
vasoconstriction, including thromboxane A2, reduction of vasodi-
lator prostaglandins, activation of renal sympathetic nerves, en-
dothelin, angiotensin 11, platelet-derived growth factor, and re-
duced nitric oxide production [10, 12, 14, 101—108]. In the isolated
perfused rat kidney, Rossi et al [109] showed that cyclosporine-
induced vasoconstriction could be blocked by alpha-adrencrgic
blockers as well as by calcium channel blockers [109]. Many in vivo
studies have evaluated the ability of pharmacologic antagonists of
mediators to reverse cyclosporine-induced vasoconstriction [110—
113]. While there are usually improvements in renal hemodynam-
ics, the effect of any individual or combination of mediators on the
chronic nephrotoxic lesion remains unknown.
Clinically, multivariate analysis of renal biopsies from cyclo-
sporine-treated patients with autoimmune disease has shown that
initial dose, male gender, and episodes of acute renal dysfunction
are major risk factors for the chronic pathologic manifestations of
cyclosporine nephropathy [56]. Mihatsch et a! [161 observed
obliterative arteriolopathy with downstream glomerulosclerosis in
cyclosporine-treated patients. They proposed that the arteriolopa.
thy with ultimate vascular occlusion produces a pattern of striped
interstitial fibrosis with nephron dropout, tubular atrophy, and, if
progressive, compromised renal function. Myers et al [23] also
suggested that chronic afferent vascular injury leads to compro-
misc in the integrity of afferent arterioles, leading to the irrevers-
ible changes that are observed.
This logical, but undocumented, pathophysiology has recently
been brought into question by several unrelated observations.
Ghiggheri et al [114] have shown that very small doses of
cyclosporine, much less than would produce toxicity clinically, can
stimulate collagen synthesis in vitro in a variety of cell systems.
Wolf and Nielson showed increased levels of type I and type 4
collagen mRNA in murine kidneys treated with CsA for four
weeks when serum creatinine was normal [115]. In an animal
model of chronic cyclosporine nephrotoxicity produced by one
week of salt depletion, structural lesions are seen that resemble
the human renal pathology of chronic cyclosporine nephropathy
[116, 117]. Indeed, afferent arteriolopathy with hyalinization and
striped tubulointerstitial fibrosis are seen when cyclosporine
treated animals arc subjected to salt depletion. Renal hemody-
namic changes are associated with this lesion. However, when the
drug is stopped, GFR returns towards baseline values over two to
four weeks while tubulointerstitial pathologic changes remain
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unchanged thus dissociating structure from function [117]. Re-
cently, it has been shown that arteriolopathy produced in this
model, while seemingly irreversible in short term follow-up
(weeks), can remit somewhat months after the drug is discontin-
ued [118].
Because the structural changes in this model are related to the
manipulation of salt depletion, the renin-angiotensin system has
been examined for its role in chronic cyclosporine nephropathy
[1191. Blockade by angiotensin converting enzyme inhibition as
well as angiotensin II receptor blockade strikingly reduces the
tubulointerstitial fibrosis and arteriolopathy in this model despite
failure to normalize glomerular filtration rate [100, 120]. Kon,
Hunley and Fogo [105] have recently shown that endothelin A and
B receptor blockade normalizes renal hemodynamics but has no
effect on the structural lesions produced in the low salt cyclospo-
rifle model, whereas angiotensin converting enzyme inhibition
normalizes renal structure without changing renal functional
parameters. Young et al [121, 122] have shown that macrophage
infiltration occurs early in this chronic model and is associated
with up-regulation of the macrophage chemoattraetant, osteopon-
tin in proximal tubular cells. Jackson, O'Connor and Humes [123]
and Rogers et a! [124] have previously shown that infiltrating cells
could be a source of vasoconstrictive prostaglandins or other
mediators of inflammation. Thus, salt depletion might turn on
angiotensin II dependent growth factors for fibroblasts, lympho-
kines, and cytokines and provide a link between the acute vascular
effects of cyclosporine and chronic tubulointerstitial damage
[125]. yclosporine increases the recruitment of renin-containing
cells along the afferent arteriole [126, 127] and the expression of
ATI receptors and renin [128]. These observations are further
strengthened by the experiments of Johnson Ct a! [129], who
showed that angiotensin 11 infusions can also produce tubuloin-
terstitial nephropathy similar to what is observed in the cyclospor-
inc-treated animals associated with up-regulation of osteopontin
in tubular cells. Furthermore, the location of the angiotensin II
type 1 receptor in the outer medulla and medullary rays [1301
corresponds to the location of damage in the chronic cyclosporine
model. When patients are converted from cyclosporine to aza-
thioprine, the number of renin containing cells and juxtaglomer-
ular apparatus hyperplasia markedly decreased over the ensuing
year [131].
The most accepted mechanism for the immunosuppressive
action of cyclosporine is the drug's interference with interleukin 2
gene transcription by interference by a cyclosporine-cyclophilin
complex inhibiting calcineurin phosphatase. It has been suggested
that cyclosporine may produce its immunosuppression not only
through inhibition of calcineurin phosphatase, hut also through
transforming growth factor (TGF) beta-mediated mechanisms
[132, 133]. This is of interest since TGFf3 may play a role in the
interstitial fibrosis of the chronic cyclosporine model [134]. Cy-
closporine enhances the expression of TGF in the juxtaglomer-
ular cells of the rat kidney [135]. Therefore, as suggested by the
work of Khanna et a! [136, 137], cyclosporine immunosuppressive
actions could also lead to the production of cytokines that lead to
renal interstitial scarring. On the one hand, effective immunosup-
pression with cyclosporine prevents rejection-induced inflamma-
tory changes that enhance fibrosis, whereas, on the other hand,
the immunosuppressive action of the drug depends on liberation
of cytokines that are pivotal in the renal scarring process.
The role of other inhibitors of renal scarring, such as cortico-
steroids, have not been clearly evaluated in cyclosporine nephro-
toxicity. It is possible that a complex relationship between a!-
lograft rejection, renal scarring, and modifying effects of
corticosteroids goes on within the renal parenchyma of an indi-
vidual patient. Preliminary evidence has shown that glucocorti-
coids reduce the morphologic changes induced in the chronic
salt-depleted rat model [138]. Further study of this area should
prove fruitful with major clinical implications for long-term
immunosuppressive withdrawal protocols. It is of interest that
cyclosporine has been observed to be protective against ischemic
reperfusion effects on mitochondria in some systems such as the
isolated rat heart [139] and forebrain [1401. Perhaps the presence
of cyclosporine modifies isehemic induced damage that would
otherwise be produced by rejection, organ procurement condi-
tions, or the hemodynamic effects of the drug per Se.
There are other possible mechanisms of cyclosporine nephro-
toxicity that have not been completely explored. Cyclosporine is
an inhibitor of the multi-drug resistance transporter, p-glycopro-
tein, which is expressed on resistant tumor cells rendering them
more sensitive to chemotherapy. This transporter is also consti-
tutively expressed on the epithelial cells of renal tubular epithe-
hum [141]. Cyclosporine, tacrolimus, and many related com-
pounds such as verapamil, inhibit this transporter and thus at least
theoretically could allow the accumulation of chemotherapeutic
agents, and perhaps other endogenous or exogenous molecules.
Cyclosporine, its metabolites, and even some of its non-immuno-
suppressive analogues, can inhibit this transporter which might
account for nephrotoxicity through indirect mechanisms. Vera-
pamil by competition for this transporter might reduce cyclospo-
rifle accumulation in tubular cells rather than by inhibition of
cyclosporine metabolism per Se. Further studies are obviously
needed in this area. Possible pathogenetic constructs and working
hypotheses are depicted in Figures 1 and 2.
Clinical issues in chronic cyclosporine nephropathy
At the present time, it is not possible to say what role chronic
cyclosporine treatment plays in the chronic failure of renal
allografts. Clearly, the drug may produce renal pathologic changes
that are deleterious. Toxic effects of cyclosporine could coexist
with those produced by chronic rejection or alternatively inade-
quate doses of cyclosporine might actually contribute to progres-
sive graft failure. There have been no properly controlled studies
to examine this point. The only data that exists are retrospective
analyses of large data sets which do not examine this issue directly.
This is an important question, because cyclosporine has some
efficacy in primary renal diseases. It would obviously not be
desirable to have chronic tubulointerstitia! disease accelerate as
glomerular lesions are brought under control.
Data on eyclosporine withdrawal protocols have been conflict-
ing. Multiple reports show a 20 to 50% incidence of post-
conversion acute rejection with about 20% of these being irre-
versible when the drug is abruptly withdrawn [142]. Other studies
are more supportive of withdrawal protocols. Pedersen et a! [143]
withdrew cyelosporine and followed the patients for one year and
compared them with patients in whom cyclosporine was contin-
ued. At the end of one year follow-up, biopsies showed little
difference in tubulointerstitial fibrosis, although vasculopathy and
blood pressure were improved in the patients in whom cyclospo-
rine was discontinued. Hollander et al [144] in a randomized study
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Rejection
Fig. 1. Proposed pathogenesis of chronic
cyclosporine nephropathy in kidney
transplantation.
Tubular cell Cancer cell
Fig. 2. Alternative hypothesis for cyclosporine
nephrotoxicity. P-glycoprotein, the multi-drug
resistance (MDR) transporter is constitutively
expressed in proximal tubular epithelium. This
transporter is inhibited by cyclosporine,
tacrolimus, and other drugs such as verapamil.
Inhibition of MDR has been used to
"chemosensitize" cancer cells. It could be
responsible for accumulation of an endogenous
toxin or toxic metabolite.
showed superior renal function in patients withdrawn from cyclo-
sporine three months post-transplant compared to control pa-
tients in whom the drug was continued over five years of follow-
up. These prospective data contrast with large retrospective
studies that conclude that inadequate cyclosporine doses, not
toxicity, leads to worse graft outcome [18]. In the retrospective
studies cyclosporine may have been reduced because of drug-
induced renal dysfunction as opposed to the conclusion that
inadequate immunosuppression leads to graft loss. These latter
studies are also flawed, by the lack of any corroborating patho-
logic data. The role of corticosteroids in cyclosporine withdrawal
protocols remains to be established. A multicenter study, with
combinations of appropriate renal functional markers and renal
pathologic studies, is needed to directly examine these questions
at least in the kidney transplant patient in whom biopsies are easy
to obtain.
Calcium antagonists may modify the metabolism of cyclospo-
rine allowing lower doses to achieve adequate immunosuppres-
sion as well as providing renal vasodilation [145—147]. Dihydro-
pyridine calcium channel blockers may slow interstitial fibrosis in
renal transplant recipients without affecting cyclosporine metab-
olism. The mechanisms of this beneficial effect is unclear [1481
although protection from daily drug related vasoconstriction is
possible [149].
Continued work in the basic science laboratories and clinics
should give us insights into the nature of cyclosporine-induced
scarring processes and their potential for modification by medical
management.
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